Novartis India to buy Pfizer Minipres trademarks for $132m
Novartis India agreed to pay Rs12.5bn ($132m) to acquire Pfizer’s Minipres and Minipress trademarks in India and related intellectual property rights. The Novartis board approved the deal and the company signed asset purchase and trademark assignment documents. The timing aligns with Pfizer ending manufacture of Minipress XL, while the acquisition expands Novartis’ cardiovascular and BPH portfolio.